Approved Is Not One State

Question

How should a research system represent the current U.S. evidence state of anti-amyloid treatments for early Alzheimer’s disease without collapsing approval, formulation, label requirements, safety updates, Medicare coverage, registry participation, and continuing trials into one misleading status?

Decision context

The demonstration is designed for research, publishing, governance, and executive briefing. It can help a qualified team identify:

• which product and formulation an official record concerns;
• which patient population was studied and appears in the approved indication;
• which safety and monitoring records changed after initial approval;
• which coverage policy applies and what evidence-development structure it uses;
• which clinical trial record supports a claim;
• which questions require a clinician, payer, regulator, or trial investigator.

It cannot determine whether any person should receive, continue, pause, or stop treatment.

Entity model

• Disease state: Alzheimer’s disease, mild cognitive impairment due to Alzheimer’s disease, mild Alzheimer’s dementia
• Pathology: confirmed amyloid beta pathology
• Products: Leqembi, lecanemab-irmb; Kisunla, donanemab-azbt
• Formulations and routes: intravenous treatment; approved Leqembi subcutaneous starting and maintenance options as described by FDA
• Evidence objects: FDA approval action, current label, safety communication, trial record, CMS national coverage determination, CMS-approved registry or study
• Safety concept: amyloid-related imaging abnormalities, including ARIA-E and ARIA-H
• Risk modifiers described in official records: ApoE ε4 status, imaging findings, anticoagulant use, and other label-specific factors
• Actors: FDA, CMS, prescribing clinician, imaging service, registry operator, sponsor, patient, caregiver
• Decisions: regulatory approval, labeling, safety monitoring, coverage, registry inclusion, clinical care

Event chronology

1. April 7, 2022 CMS issued National Coverage Determination 200.3 for FDA-approved monoclonal antibodies directed against amyloid under Coverage with Evidence Development for the specified early-Alzheimer’s population and evidence settings. MED-S07

1. January 6, 2023 FDA granted accelerated approval to Leqembi. MED-S01

1. July 6, 2023 FDA converted Leqembi to traditional approval after the confirmatory CLARITY AD study verified clinical benefit. MED-S01MED-S09

1. July 2, 2024 FDA approved Kisunla for Alzheimer’s disease. FDA states that treatment should be initiated in the population studied, people with mild cognitive impairment or mild dementia stage of disease, and the prescribing information contains a boxed warning for ARIA. MED-S03MED-S04MED-S10

1. August 28, 2025 FDA announced an additional earlier MRI-monitoring requirement for Leqembi before the third infusion after reviewing serious and fatal ARIA-E reports early in treatment. MED-S02

1. FDA page dated July 13, 2026 FDA approved a Leqembi subcutaneous starting regimen that permits at-home administration by a patient or caregiver. FDA explained that the subcutaneous formulation was supported by the intravenous formulation’s clinical outcome evidence plus pharmacokinetic and amyloid-plaque evidence, rather than a separate large clinical-outcome trial of the subcutaneous formulation. MED-S05

1. November 1, 2026 evidence refresh ClinicalTrials.gov lists CLARITY AD and TRAILBLAZER-ALZ 2 as active, not recruiting, with continuing extension or follow-up activity. CMS continues to list its NCD, national registry, and qualifying CED studies. MED-S06MED-S07MED-S08MED-S09MED-S10

Source register

Claim register

Observed

MED-O-001 FDA granted Leqembi traditional approval on July 6, 2023 after a confirmatory trial verified clinical benefit. MED-S01MED-S09

MED-O-002 FDA approved Kisunla on July 2, 2024 based on evidence that included TRAILBLAZER-ALZ 2. MED-S03MED-S04MED-S10

MED-O-003 Both products are indicated for Alzheimer’s disease, with treatment initiation described for patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was studied. Official records also require or describe confirmation of amyloid pathology. MED-S01MED-S03MED-S11MED-S12

MED-O-004 Both prescribing-information records contain prominent ARIA safety warnings, and official records describe greater ARIA risk in ApoE ε4 homozygotes. MED-S01MED-S03MED-S11MED-S12

MED-O-005 In August 2025, FDA required an additional earlier MRI before the third Leqembi infusion after reviewing serious and fatal early-treatment ARIA-E reports. MED-S02

MED-O-006 In July 2026, FDA approved a Leqembi subcutaneous starting regimen for at-home administration. FDA expressly distinguished the formulation’s evidence basis from a separate large clinical-outcome trial. MED-S05

MED-O-007 CMS NCD 200.3 covers qualifying FDA-approved anti-amyloid monoclonal antibodies under Coverage with Evidence Development for the specified early-Alzheimer’s population and evidence settings. CMS maintains a list of qualifying studies and registry pathways. MED-S06MED-S07MED-S08

MED-O-008 The two pivotal-trial records remain active, not recruiting, because extension or long-term follow-up activity continues beyond the original primary analyses. MED-S09MED-S10

Corroborated

MED-C-001 “FDA approved” is not a complete operational status. The official evidence state also includes the exact product, formulation, patient population, current label, later safety communications, monitoring requirements, payer policy, registry structure, and continuing follow-up evidence. [MED-S01 through MED-S12]

MED-C-002 Approval and Medicare coverage are separate official decisions made by different agencies under different authorities. MED-S01MED-S03MED-S06MED-S07

MED-C-003 A formulation update can change route and setting without erasing the original clinical-outcome evidence chain or the existing safety and monitoring framework. MED-S02MED-S05MED-S09MED-S11

Derived

MED-D-001 A responsible intelligence record should store regulatory status, formulation, route, indication, label version, safety communication, monitoring schedule, coverage pathway, registry requirement, and trial status as separate versioned fields.

MED-D-002 The phrase “at-home treatment” is incomplete unless it identifies the approved formulation, starting or maintenance context, administrator, current label, and continuing clinical-supervision requirements.

MED-D-003 Continuing trial activity does not reverse approval. It means the evidence record remains active and should not be frozen at the approval date.

Inferred

MED-I-001 A research team that stores only approval date and brand name will be unable to explain later safety changes, formulation transitions, coverage conditions, or evidentiary differences.

MED-I-002 For publication or operational use, each public claim should resolve to a dated official source and be reviewed by qualified medical, regulatory, and coverage specialists where the claim affects care.

These are Delta Arc systems inferences, not clinical recommendations.

Contradictions, limits, and unknowns

• A regulatory approval does not mean a product is appropriate for every person with Alzheimer’s disease.
• A route or formulation change does not prove identical real-world outcomes in every setting.
• The FDA’s July 2026 page states that the subcutaneous formulation was not separately tested in a large clinical-outcome trial. The evidence bridge and current label must remain visible.
• CMS coverage policy, private coverage, provider capacity, imaging access, registry workflows, and patient cost are different questions.
• Trial status can remain active after primary results because extension or follow-up work continues.
• Safety communications and labels can change. Delta Arc did not confirm at release that the labels listed here are the newest versions. Check Drugs@FDA for the current label.
• Public sources do not establish a patient’s diagnosis, stage, amyloid status, genotype, imaging findings, medications, contraindications, preferences, or benefit-risk assessment.
• Delta Arc does not determine whether a patient meets treatment or coverage criteria.

Safe Delta Arc outputs

• Versioned evidence-state map
• Approval and formulation chronology
• Label and safety-update tracker
• Coverage and registry pathway map
• Trial-to-approval provenance graph
• Source-linked executive brief
• Qualified-review question list
• Change alert that identifies what changed and what did not

Prohibited outputs

• Diagnosis or screening decision
• Treatment selection, dosing, initiation, continuation, interruption, or discontinuation advice
• Patient eligibility determination
• MRI interpretation or monitoring instruction
• Genotype interpretation for an individual
• Coverage guarantee or benefits determination
• Benefit-risk conclusion for a person
• Claim that approval means cure, universal eligibility, or guaranteed benefit
• Autonomous clinical workflow

Changes made at release

• The current label check could not be completed at release, so the page says so.
• This row no longer calls the listed label current.
• The date shown is the date on FDA's page.